12,070.00
+60.00
+(0.50%)
At close: January 17 at 3:30:30 PM GMT+9
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
251,728,777.70
230,393,578.98
198,934,734.39
177,775,700.61
171,705,404.97
Cost of Revenue
155,336,342.55
131,232,965.77
100,141,739.60
84,283,355.57
85,103,292.54
Gross Profit
96,392,435.15
99,160,613.21
98,792,994.79
93,492,345.04
86,602,112.43
Operating Expense
69,359,267.00
68,990,325.00
68,982,575.00
62,216,550.00
58,183,801.00
Operating Income
27,033,168.15
30,170,288.21
29,810,419.79
31,275,795.04
28,418,311.43
Net Non Operating Interest Income Expense
2,745,954.54
3,316,617.73
2,108,192.83
1,430,952.30
1,571,468.65
Pretax Income
31,572,053.60
33,793,312.33
29,808,164.08
33,881,528.30
31,081,793.16
Tax Provision
4,208,417.24
4,018,990.16
6,074,577.35
7,423,022.24
7,890,495.51
Net Income Common Stockholders
27,363,636.35
29,774,322.16
23,921,351.11
26,659,600.06
23,387,790.17
Basic EPS
1.79k
1.95k
1.57k
1.75k
1.53k
Diluted EPS
1.79k
1.95k
1.57k
1.75k
1.53k
Basic Average Shares
15,269.35
15,268.88
15,265.70
15,268.96
15,266.18
Diluted Average Shares
15,269.35
15,268.88
15,265.70
15,268.96
15,266.18
Total Operating Income as Reported
27,033,168.36
30,170,287.86
29,810,419.72
31,275,795.11
28,418,311.69
Rent Expense Supplemental
273,613.00
245,902.00
191,030.00
114,272.00
114,980.00
Total Expenses
224,695,609.55
200,223,290.77
169,124,314.60
146,499,905.57
143,287,093.54
Net Income from Continuing & Discontinued Operation
27,363,636.35
29,774,322.16
23,921,351.11
26,659,600.06
23,387,790.17
Normalized Income
27,361,370.78
29,986,584.60
26,323,761.60
26,544,171.05
22,664,803.63
Interest Income
2,767,312.00
3,339,274.00
2,160,069.00
1,482,504.00
1,602,885.00
Interest Expense
21,357.00
22,656.00
51,876.00
51,552.00
31,416.00
Net Interest Income
2,745,954.54
3,316,617.73
2,108,192.83
1,430,952.30
1,571,468.65
EBIT
31,593,410.60
33,815,968.33
29,860,040.08
33,933,080.30
31,113,209.16
EBITDA
39,472,316.08
40,475,357.93
34,706,794.41
38,135,051.05
35,183,040.12
Reconciled Cost of Revenue
155,336,342.55
131,232,965.77
100,141,739.60
84,283,355.57
85,103,292.54
Reconciled Depreciation
7,878,905.48
6,659,389.60
4,846,754.33
4,201,970.75
4,069,830.96
Net Income from Continuing Operation Net Minority Interest
27,363,636.35
29,774,322.16
23,921,351.11
26,659,600.06
23,387,790.17
Total Unusual Items Excluding Goodwill
2,614.00
-240,914.00
-3,017,304.00
147,813.00
968,972.00
Total Unusual Items
2,614.00
-240,914.00
-3,017,304.00
147,813.00
968,972.00
Normalized EBITDA
39,469,702.08
40,716,271.93
37,724,098.41
37,987,238.05
34,214,068.12
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
348.43
-28,651.56
-614,893.51
32,383.99
245,985.46
12/31/2020 - 1/4/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
293480.KS Hana Pharm Co., Ltd.
10,470.00
+0.10%
001060.KS JW Pharmaceutical Corporation
23,250.00
-1.06%
185750.KS Chong Kun Dang Pharmaceutical Corp.
91,000.00
-1.09%
234080.KS JW Lifescience Corporation
10,710.00
-0.28%
069620.KQ 069620.KQ,0P0000BXZW,24919
118,200.00
-0.84%
096760.KS JW Holdings Corporation
2,995.00
-0.50%
069620.KS Daewoong Pharmaceutical Co., Ltd
130,000.00
-0.23%
128940.KS Hanmi Pharm. Co., Ltd.
255,500.00
-0.97%
006280.KS GC Biopharma Corp.
146,400.00
-9.35%
TKPHF Takeda Pharmaceutical Company Limited
24.35
0.00%